{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:26:36Z","timestamp":1793834796696,"version":"4.6.1"},"reference-count":20,"publisher":"American Academy of Pediatrics (AAP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,1]]},"abstract":"<jats:sec>\n                    <jats:title>CONTEXT<\/jats:title>\n                    <jats:p>Severe hyperbilirubinemia is associated with kernicterus. Informed guidance on hyperbilirubinemia management, including preventive treatment thresholds, is essential to safely minimize neurodevelopmental risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>To update the evidence base necessary to develop the 2022 American Academy of Pediatrics clinical practice guideline for management of hyperbilirubinemia in the newborn infant \u226535 weeks\u2019 gestation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SOURCE<\/jats:title>\n                    <jats:p>PubMed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>STUDY SELECTION<\/jats:title>\n                    <jats:p>English language randomized controlled trials and observational studies. Excluded: case reports or series, nonsystematic reviews, and investigations focused on &amp;lt;35-weeks\u2019 gestation infants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA EXTRACTION<\/jats:title>\n                    <jats:p>Topics addressed in the previous clinical practice guideline (2004) and follow-up commentary (2009) were updated with new evidence published through March 2022. Evidence reviews were conducted for previously unaddressed topics (phototherapy-associated adverse effects and effectiveness of intravenous immune globulin [IVIG] to prevent exchange transfusion).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>New evidence indicates that neurotoxicity does not occur until bilirubin concentrations are well above the 2004 exchange transfusion thresholds. Systematic review of phototherapy-associated adverse effects found limited and\/or inconsistent evidence of late adverse effects, including cancer and epilepsy. IVIG has unclear benefit for preventing exchange transfusion in infants with isoimmune hemolytic disease, with a possible risk of harm due to necrotizing enterocolitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>LIMITATIONS<\/jats:title>\n                    <jats:p>The search was limited to 1 database and English language studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>Accumulated evidence justified narrowly raising phototherapy treatment thresholds in the updated clinical practice guideline. Limited evidence for effectiveness with some evidence of risk of harm support the revised recommendations to limit IVIG use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1542\/peds.2022-058865","type":"journal-article","created":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T23:08:40Z","timestamp":1659654520000},"source":"Crossref","is-referenced-by-count":82,"title":["Technical Report: Diagnosis and Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation"],"prefix":"10.1542","volume":"150","author":[{"given":"Jonathan L.","family":"Slaughter","sequence":"first","affiliation":[{"name":"aCenter for Perinatal Research"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex R.","family":"Kemper","sequence":"additional","affiliation":[{"name":"cDepartments of Epidemiology & Biostatistics and Pediatrics, University of California, San Francisco, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas B.","family":"Newman","sequence":"additional","affiliation":[{"name":"bDivision of Primary Care Pediatrics, Nationwide Children's Hospital, Columbus, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2022,8,5]]},"reference":[{"issue":"3","key":"2024072415161236300_B1","doi-asserted-by":"crossref","first-page":"e2022058859","DOI":"10.1542\/peds.2022-058859","article-title":"Clinical practice guideline revision: Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation","volume":"150","author":"Kemper","year":"2022","journal-title":"Pediatrics"},{"issue":"1","key":"2024072415161236300_B2","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1542\/peds.114.1.297","article-title":"Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation","volume":"114","author":"Maisels","year":"2004","journal-title":"Pediatrics"},{"issue":"4","key":"2024072415161236300_B3","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1542\/peds.2009-0329","article-title":"Hyperbilirubinemia in the newborn infant &gt; or =35 weeks\u2019 gestation: an update with clarifications","volume":"124","author":"Maisels","year":"2009","journal-title":"Pediatrics"},{"key":"2024072415161236300_B4","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/B978-0-323-42876-7.00026-0","article-title":"Bilirubin","volume-title":"Volpe's Neurology of the Newborn","author":"Perlman","year":"2018"},{"issue":"3","key":"2024072415161236300_B5","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1542\/peds.2014-0987","article-title":"Incidence, etiology, and outcomes of hazardous hyperbilirubinemia in newborns","volume":"134","author":"Kuzniewicz","year":"2014","journal-title":"Pediatrics"},{"issue":"3","key":"2024072415161236300_B6","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1542\/peds.2014-3357","article-title":"Risk of sensorineural hearing loss and bilirubin exchange transfusion thresholds","volume":"136","author":"Wickremasinghe","year":"2015","journal-title":"Pediatrics"},{"issue":"3","key":"2024072415161236300_B7","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/jamapediatrics.2014.3036","article-title":"Risk for cerebral palsy in infants with total serum bilirubin levels at or above the exchange transfusion threshold: a population-based study","volume":"169","author":"Wu","year":"2015","journal-title":"JAMA Pediatr"},{"issue":"18","key":"2024072415161236300_B8","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa054244","article-title":"Outcomes among newborns with total serum bilirubin levels of 25 mg per deciliter or more","volume":"354","author":"Newman","year":"2006","journal-title":"N Engl J Med"},{"issue":"4","key":"2024072415161236300_B9","doi-asserted-by":"crossref","first-page":"e925","DOI":"10.1542\/peds.2011-0206","article-title":"Risk factors for neurotoxicity in newborns with severe neonatal hyperbilirubinemia","volume":"128","author":"Gamaleldin","year":"2011","journal-title":"Pediatrics"},{"issue":"4","key":"2024072415161236300_B10","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/dmcn.12603","article-title":"Follow-up of extreme neonatal hyperbilirubinaemia in 5- to 10-year-old children: a Danish population-based study","volume":"57","author":"Vandborg","year":"2015","journal-title":"Dev Med Child Neurol"},{"issue":"4","key":"2024072415161236300_B11","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/j.1651-2227.2011.02565.x","article-title":"Relation between serum bilirubin levels \u2265450 \u03bcmol\/L and bilirubin encephalopathy; a Danish population-based study","volume":"101","author":"Ebbesen","year":"2012","journal-title":"Acta Paediatr"},{"issue":"4","key":"2024072415161236300_B12","doi-asserted-by":"crossref","first-page":"e20180648","DOI":"10.1542\/peds.2018-0648","article-title":"Childhood seizures after phototherapy","volume":"142","author":"Newman","year":"2018","journal-title":"Pediatrics"},{"issue":"6","key":"2024072415161236300_B13","doi-asserted-by":"crossref","first-page":"e20151353","DOI":"10.1542\/peds.2015-1353","article-title":"Neonatal phototherapy and infantile cancer","volume":"137","author":"Wickremasinghe","year":"2016","journal-title":"Pediatrics"},{"key":"2024072415161236300_B14","unstructured":"American Academy of Pediatrics\n          . Evidence-based clinical practice guidelines development and implementation manual. Available at: https:\/\/www.aap.org\/en-us\/professional-resources\/quality- improvement\/clinical-practice- guideline-manual\/Pages\/default.aspx. Accessed May 30, 2019"},{"issue":"8","key":"2024072415161236300_B15","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1002\/ijc.32158","article-title":"Neonatal phototherapy and future risk of childhood cancer","volume":"145","author":"Auger","year":"2019","journal-title":"Int J Cancer"},{"issue":"6","key":"2024072415161236300_B16","doi-asserted-by":"crossref","first-page":"e20151354","DOI":"10.1542\/peds.2015-1354","article-title":"Retrospective cohort study of phototherapy and childhood cancer in Northern California","volume":"137","author":"Newman","year":"2016","journal-title":"Pediatrics"},{"key":"2024072415161236300_B17","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.eplepsyres.2016.05.004","article-title":"Neonatal hyperbilirubinemia and the risk of febrile seizures and childhood epilepsy","volume":"124","author":"Maimburg","year":"2016","journal-title":"Epilepsy Res"},{"issue":"7","key":"2024072415161236300_B18","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"issue":"1","key":"2024072415161236300_B19","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1542\/peds.2009-0676","article-title":"Intravenous immunoglobulin and necrotizing enterocolitis in newborns with hemolytic disease","volume":"125","author":"Figueras-Aloy","year":"2010","journal-title":"Pediatrics"},{"issue":"18","key":"2024072415161236300_B20","first-page":"3902","article-title":"The effect of immunoglobulin treatment for hemolysis on the incidence of necrotizing enterocolitis - a meta-analysis","volume":"20","author":"Yang","year":"2016","journal-title":"Eur Rev Med Pharmacol Sci"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2022-058865\/1677527\/peds_2022058865.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2022-058865\/1677527\/peds_2022058865.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T13:15:52Z","timestamp":1721826952000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/150\/3\/e2022058865\/188725\/Technical-Report-Diagnosis-and-Management-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,5]]},"references-count":20,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,8,5]]},"published-print":{"date-parts":[[2022,9,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2022-058865","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,5]]},"article-number":"e2022058865"}}